{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:39Z","timestamp":1766514159510,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ijantimicag.2019.10.021","type":"journal-article","created":{"date-parts":[[2019,11,5]],"date-time":"2019-11-05T12:10:00Z","timestamp":1572955800000},"page":"105840","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluation of super-boosted lopinavir\/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis"],"prefix":"10.1016","volume":"55","author":[{"given":"Catherine","family":"Boulanger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Rolla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1432-5175","authenticated-orcid":false,"given":"Mohammad H.","family":"Al-Shaer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles","family":"Peloquin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2019.10.021_bib0001","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/S1473-3099(17)30702-8","article-title":"HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis","volume":"18","author":"Gupta","year":"2017","journal-title":"Lancet Infect Dis"},{"year":"2013","series-title":"Managing drug interactions in the treatment of HIV-related tuberculosis","key":"10.1016\/j.ijantimicag.2019.10.021_bib0002"},{"key":"10.1016\/j.ijantimicag.2019.10.021_bib0003","doi-asserted-by":"crossref","first-page":"e44793","DOI":"10.1371\/journal.pone.0044793","article-title":"Coadministration of lopinavir\/ritonavir and rifampicin in HIV and tuberculosis co-infected adults in South Africa","volume":"7","author":"Murphy","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.10.021_bib0004","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/QAD.0b013e328329148e","article-title":"Clinical experience with the combined use of lopinavir\/ritonavir and rifampicin","volume":"23","author":"L'Homme","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.ijantimicag.2019.10.021_bib0005","doi-asserted-by":"crossref","first-page":"e32173","DOI":"10.1371\/journal.pone.0032173","article-title":"The safety, effectiveness and concentrations of adjusted lopinavir\/ritonavir in HIV-infected adults on rifampicin-based antitubercular therapy","volume":"7","author":"Decloedt","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2019.10.021_bib0006","doi-asserted-by":"crossref","first-page":"689","DOI":"10.5588\/ijtld.13.0492","article-title":"Double-dose lopinavir\u2013ritonavir in combination with rifampicin-based anti-tuberculosis treatment in South Africa","volume":"18","author":"Sunpath","year":"2014","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.ijantimicag.2019.10.021_bib0007","first-page":"358","article-title":"Pharmacological interaction of lopinavir\/ritonavir 800\/200 mg BID and rifampicin in subjects presenting tuberculosis with contraindication for an efavirenz containing antiretroviral regimen","volume":"5","author":"Stanis Schmaltz","year":"2014","journal-title":"J AIDS Clin Res"},{"key":"10.1016\/j.ijantimicag.2019.10.021_bib0008","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1128\/AAC.48.11.4473-4475.2004","article-title":"Decreased bioavailability of rifampin and other antituberculosis drugs in patients with advanced human immunodeficiency virus disease","volume":"48","author":"Gurumurthy","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2019.10.021_bib0009","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1590\/S1413-86702009000300011","article-title":"Intestinal barrier function and serum concentrations of rifampin, isoniazid and pyrazinamide in patients with pulmonary tuberculosis","volume":"13","author":"Fa\u00e7anha","year":"2009","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2019.10.021_bib0010","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1590\/S1413-86702006000600003","article-title":"Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis","volume":"10","author":"Pinheiro","year":"2006","journal-title":"Braz J Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919303012?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857919303012?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:33:52Z","timestamp":1760376832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857919303012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S0924857919303012"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.10.021","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of super-boosted lopinavir\/ritonavir in combination with rifampicin in HIV-1-infected patients with tuberculosis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2019.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105840"}}